Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab

被引：5

作者：

Shao, Ning ^{[1
,2
]}

Wan, Fangning ^{[1
,2
]}

Zhu, Yao ^{[1
,2
]}

Ye, Dingwei ^{[1
,2
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Dept Urol, Shanghai, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China

来源：

MEDICAL SCIENCE MONITOR | 2019年 / 25卷

基金：

中国国家自然科学基金;

关键词：

Carcinoma; Renal Cell; Immunotherapy; Survival; RESECTION;

D O I：

10.12659/MSM.916984

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (COS) and conditional progression-free survival (CPFS) in patients with advanced RCC treated with nivolumab. Material/Methods: There were 847 patients with advanced RCC treated with first-line nivolumab plus ipilimumab (n=425) and sunitinib (n=422), and 821 patients were treated with second-line nivolumab (n=410) and everolimus (n=411). Primary endpoints were COS and CPFS. Individual patient data of PFS and OS were digitally reconstructed from two large randomized controlled trials (CheckMate 025 and CheckMate 214). Results: In first-line treatment, compared with sunitinib, improvement of one-year CPFS for the nivolumab plus ipilimumab group after living for 0.5 and 0.75 years were 14% (from 53.0% to 67.0%) and 16% (from 57.0% to 73.0%) higher than the one-year PFS of 6.5% (from 42.9% to 49.4%), with similar results for one-year COS following first-line treatment. For second-line treatment, compared with everolimus, the improvement of one-year CPFS for the nivolumab group after living for 0.5 and 0.75 years were 19% (from 25.0% to 44.0%) and 19% (from 27.0% to 46.0%) and significantly higher than the one-year PFS of 4.5% (from 18.5% to 23.0%). Conclusions: Survival benefit for patients with advanced RCC from nivolumab (plus ipilimumab) compared with sunitinib was more evident from conditional survival (CS) analysis of first-line treatment.

引用

页码：6518 / 6522

页数：5

共 13 条

[1] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer [J].

Aguiar, Pedro N., Jr. ;

Haaland, Benjamin ;

Park, Wungki ;

Tan, Pui San ;

del Giglio, Auro ;

Lopes, Gilberto de Lima, Jr. .

JAMA ONCOLOGY, 2018, 4 (08) :1080-1084

[2] A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations [J].

Bex, Axel ;

Albiges, Laurence ;

Staehler, Michael ;

Bensalah, Karim ;

Giles, Rachel H. ;

Dabestani, Saeed ;

Hofmann, Fabian ;

Hora, Milan ;

Kuczyk, Markus A. ;

Lam, Thomas B. ;

Marconi, Lorenzo ;

Merseburger, Axel S. ;

Fernandez-Pello, Sergio ;

Tahbaz, Rana ;

Abu-Ghanem, Yasmin ;

Volpe, Alessandro ;

Ljungberg, Borje ;

Escudier, Bernard ;

Powles, Thomas .

EUROPEAN UROLOGY, 2018, 74 (06) :849-851

[3] Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients [J].

Cucchetti, Alessandro ;

Piscaglia, Fabio ;

Cescon, Matteo ;

Ercolani, Giorgio ;

Terzi, Eleonora ;

Bolondi, Luigi ;

Zanello, Matteo ;

Pinna, Antonio D. .

CLINICAL CANCER RESEARCH, 2012, 18 (16) :4397-4405

[4] Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study [J].

Harshman, Lauren C. ;

Xie, Wanling ;

Bjarnason, Georg A. ;

Knox, Jennifer J. ;

MacKenzie, Mary ;

Wood, Lori ;

Srinivas, Sandy ;

Vaishampayan, Ulka N. ;

Tan, Min-Han ;

Rha, Sun-Young ;

Donskov, Frede ;

Agarwal, Neeraj ;

Kollmannsberger, Christian ;

North, Scott ;

Rini, Brian I. ;

Heng, Daniel Y. C. ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2012, 13 (09) :927-935

[5] FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer [J].

Higuchi, Mitsunori ;

Owada, Yuki ;

Inoue, Takuya ;

Watanabe, Yuzuru ;

Yamaura, Takumi ;

Fukuhara, Mitsuro ;

Hasegawa, Takeo ;

Suzuki, Hiroyuki .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14

[6] Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability [J].

Kim, Yuhree ;

Margonis, Georgios A. ;

Prescott, Jason D. ;

Tran, Thuy B. ;

Postlewait, Lauren M. ;

Maithel, Shishir K. ;

Wang, Tracy S. ;

Glenn, Jason A. ;

Hatzaras, Ioannis ;

Shenoy, Rivfka ;

Phay, John E. ;

Keplinger, Kara ;

Fields, Ryan C. ;

Jin, Linda X. ;

Weber, Sharon M. ;

Salem, Ahmed ;

Sicklick, Jason K. ;

Gad, Shady ;

Yopp, Adam C. ;

Mansour, John C. ;

Duh, Quan-Yang ;

Seiser, Natalie ;

Solorzano, Carmen C. ;

Kiernan, Colleen M. ;

Votanopoulos, Konstantinos I. ;

Levine, Edward A. ;

Poultsides, George A. ;

Pawlik, Timothy M. .

ANNALS OF SURGERY, 2017, 265 (01) :197-204

[7] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[8] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[9] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial [J].

Motzer, Robert J. ;

Rini, Brian I. ;

McDermott, David F. ;

Redman, Bruce G. ;

Kuzel, Timothy M. ;

Harrison, Michael R. ;

Vaishampayan, Ulka N. ;

Drabkin, Harry A. ;

George, Saby ;

Logan, Theodore F. ;

Margolin, Kim A. ;

Plimack, Elizabeth R. ;

Lambert, Alexandre M. ;

Waxman, Ian M. ;

Hammers, Hans J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) :1430-1437

[10] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis [J].

Rui, Xin ;

Gu, Ting-Ting ;

Pan, Hua-Feng ;

Zhang, Hui-Zhi .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 :378-385

← 1 2 →